AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

Several authors disclosed ties to biopharmaceutical companies. AstraZeneca provided exenatide for the study. Abstract/Full Text ...

AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...

A rigorous study that randomly assigned Parkinson’s patients to take exenatide, a relative of ... a type 2 diabetes treatment made by AstraZeneca and sold under the brand name Byetta, or with ...

AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular benefits to patients. The FDA now obliges companies with diabetes products to conduct large ...